ADAMO, BARBARA
 Distribuzione geografica
Continente #
EU - Europa 3.699
NA - Nord America 2.800
AS - Asia 1.451
SA - Sud America 467
AF - Africa 42
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 8.464
Nazione #
US - Stati Uniti d'America 2.753
RU - Federazione Russa 1.883
SG - Singapore 649
SE - Svezia 525
IE - Irlanda 444
CN - Cina 423
BR - Brasile 412
DE - Germania 170
HK - Hong Kong 152
UA - Ucraina 151
FR - Francia 122
GB - Regno Unito 102
IT - Italia 94
FI - Finlandia 81
VN - Vietnam 59
IN - India 57
PL - Polonia 44
CA - Canada 24
BE - Belgio 23
AR - Argentina 20
BD - Bangladesh 18
ZA - Sudafrica 16
IQ - Iraq 14
MX - Messico 14
AT - Austria 11
CO - Colombia 11
ID - Indonesia 11
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
MA - Marocco 9
NL - Olanda 9
PK - Pakistan 9
VE - Venezuela 9
TR - Turchia 8
JP - Giappone 7
ES - Italia 6
SA - Arabia Saudita 6
DZ - Algeria 5
JO - Giordania 5
AE - Emirati Arabi Uniti 4
EC - Ecuador 4
PE - Perù 4
CL - Cile 3
JM - Giamaica 3
LT - Lituania 3
PT - Portogallo 3
AL - Albania 2
AM - Armenia 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
EG - Egitto 2
EU - Europa 2
HU - Ungheria 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NP - Nepal 2
PA - Panama 2
PS - Palestinian Territory 2
PY - Paraguay 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
IM - Isola di Man 1
IR - Iran 1
KG - Kirghizistan 1
KR - Corea 1
MK - Macedonia 1
MY - Malesia 1
PH - Filippine 1
RS - Serbia 1
SN - Senegal 1
TH - Thailandia 1
TM - Turkmenistan 1
Totale 8.464
Città #
Moscow 523
Dublin 442
Singapore 355
Ashburn 334
Chandler 333
Jacksonville 291
Nyköping 282
Dallas 258
Beijing 167
Hong Kong 152
San Jose 132
Ann Arbor 85
The Dalles 82
Dearborn 81
Los Angeles 77
New York 72
Cambridge 64
Princeton 64
Medford 61
Lauterbourg 56
Des Moines 50
São Paulo 42
Warsaw 41
Boardman 40
Lancaster 34
Buffalo 31
Pune 29
Frankfurt am Main 27
Messina 26
Brussels 23
Tianjin 23
Orem 21
Munich 20
Hanoi 17
Ho Chi Minh City 16
Rio de Janeiro 16
Jinan 15
Guangzhou 14
Wilmington 14
Redondo Beach 13
Shenyang 13
Woodbridge 13
Brooklyn 12
Council Bluffs 12
Johannesburg 12
Boston 11
Helsinki 11
Nanjing 11
Belo Horizonte 10
Manchester 10
Tashkent 10
Montreal 9
Stockholm 9
Vienna 9
Chicago 8
London 8
Nanchang 7
Ningbo 7
Porto Alegre 7
San Mateo 7
Tokyo 7
Washington 7
Amsterdam 6
Baghdad 6
Curitiba 6
Dong Ket 6
Fortaleza 6
Grammichele 6
Haikou 6
Hebei 6
Mexico City 6
Milan 6
Mumbai 6
Olomouc 6
Poplar 6
Shenzhen 6
Turku 6
Atlanta 5
Bogotá 5
Chennai 5
Goiânia 5
Hangzhou 5
Houston 5
Jakarta 5
New Delhi 5
Nuremberg 5
Taiyuan 5
Barbacena 4
Brasília 4
Campinas 4
Casablanca 4
Denver 4
Dhaka 4
Istanbul 4
Jiaxing 4
Juiz de Fora 4
Orta di Atella 4
Osasco 4
Roubaix 4
San Francisco 4
Totale 4.825
Nome #
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 216
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 216
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 208
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 196
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 194
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 192
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 179
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 173
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 171
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 171
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 169
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 166
Breast. La terapia primaria: stato dell'arte 166
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 161
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 157
BRCA1 missense variants of uncertain clinical significance in unaffected and breast/ovarian cancer of the sicilian population. 151
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. 147
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 146
A Missense Mutation Associated to Early Onset Breast Cancer in A Sicilian Woman. 145
BRCA1 germline mutations in sicilian breast and/or ovarian cancer families and their implications for genetic counseling. 143
Embolia polmonare 142
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 141
A rare case of malignant solitary fibrous tumor of the spinal cord 140
AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome 140
A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation ? 136
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 134
Analysis of the expression levels of Leptin gene and it’s receptor in Breast Cancer patients. 132
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 131
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 128
From Adjuvant to Preventive Breast Cancer Treatment: bridging the gap over troubled waters. 128
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 127
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 123
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 121
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 121
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 120
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 120
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Sicilian family. 119
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 116
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 112
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 110
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 110
Strategia Terapeutica nel Carcinoma Prostatico Ormonorefrattario 109
Neoplasie della testa collo nell’ anziano 109
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 108
Tumor Characteristics and Adjuvant treatment in Very Young Women 106
Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study. 106
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 105
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 105
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 102
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 101
Turbe della nutrizione: anoressia e cachessia. 100
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? 100
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 99
Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy. 98
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 96
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 96
Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. 96
Primary Therapy in Breast Cancer: The State of the Art. 93
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels 91
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 91
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 89
Stratifying triple-negative breast cancer: which definition(s) to use? 87
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 85
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 59
null 52
null 37
null 33
null 22
Totale 8.493
Categoria #
all - tutte 25.754
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.754


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021121 0 0 0 0 0 0 0 0 0 49 41 31
2021/2022470 5 69 7 9 21 3 23 13 8 107 66 139
2022/20231.362 98 146 62 103 96 141 29 84 540 5 43 15
2023/2024350 22 49 19 33 30 136 36 1 7 3 4 10
2024/20251.179 9 21 24 73 60 36 10 220 336 72 133 185
2025/20263.764 154 223 250 198 344 917 575 531 469 103 0 0
Totale 8.493